On May 12, 2025, President Trump signed an executive order with the potential to significantly change the U.S. drug pricing and distribution system. Here is what we know about the Administration’s new Most Favored Nation (MFN) policy:
At Magnolia Market Access, we see frailty as a key variable in evidence generation and access strategy. Ahead of ISPOR 2025, we sat down with Mike Murphy to discuss Magnolia’s latest research using administrative claims data to evaluate frailty indices.
Magnolia Market Access analyzed a potential sliding fee scale policy, adjusting patient cost-sharing for 340B-dispensed drugs, to understand implications on out-of-pocket costs for 340B patients.
Magnolia Market Access analyzed a potential sliding fee scale policy, adjusting patient cost-sharing for 340B-dispensed drugs, to understand implications on out-of-pocket costs for 340B patients.
A biopharma company engaged Magnolia Market Access and sister company, 81qd, to collect data and segment provider and payer entities to identify key decision
makers for a novel cardiology treatment.
A large pharmaceutical company needed to
demonstrate the potential cost savings of placing a new drug on payer formularies.
A small-size pharmaceutical company was interested in using real-world evidence to compare adherence between two formulations of an oral oncology treatment for Multiple Myeloma (MM).
A mid-size pharmaceutical
company was interested in
obtaining real-world evidence
demonstrating the safety and
effectiveness of higher dosage
chemotherapy for a labeled
oncology indication.
A medium pharmaceutical company was launching a new oral drug in the diabetes space and wanted to understand how having specific income criteria for their commercial copay program would affect patient enrollment and the costs of program operation.
AMCP Spring 2024 Platinum Poster and Presentation.